XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswireFeb 4 07:30 ET

XOMA CORP 8.625% CUM PERP PFD SER A To Go Ex-Dividend On January 3rd, 2025 With 0.53906 USD Dividend Per Share

Moomoo NewsDec 19, 2024 19:45 ET

XOMA Royalty Declares Quarterly Preferred Stock Dividends

GlobeNewswireDec 19, 2024 07:30 ET

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

GlobeNewswireDec 2, 2024 07:30 ET

8-K: XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

SECNov 7, 2024 07:48 ET

10-Q: Q3 2024 Earnings Report

SECNov 7, 2024 07:38 ET · Announcements

XOMA Royalty Significantly Expands Its Royalty and Milestone Portfolio With the Addition of Over 60 Early-Stage Programs From Twist Bioscience

GlobeNewswireOct 22, 2024 08:00 ET

XOMA CORP 8.625% CUM PERP PFD SER A To Go Ex-Dividend On October 3rd, 2024 With 0.53906 USD Dividend Per Share

Moomoo NewsSep 23, 2024 19:40 ET

Zevra's MIPLYFFA (Arimoclomol) Receives Approval From U.S. Food and Drug Administration for Use in Patients With Niemann-Pick Disease Type C (NPC)

GlobeNewswireSep 23, 2024 06:30 ET

XOMA Royalty to Present at Upcoming Investor Conferences in September

GlobeNewswireSep 4, 2024 07:30 ET

8-K: XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

SECAug 13, 2024 07:47 ET

10-Q: Q2 2024 Earnings Report

SECAug 13, 2024 07:42 ET · Announcements

XOMA CORP 8.625% CUM PERP PFD SER A To Go Ex-Dividend On July 3rd, 2024 With 0.53906 USD Dividend Per Share

Moomoo NewsJun 20, 2024 19:40 ET

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of Its Priority Review Voucher

GlobeNewswireJun 12, 2024 07:30 ET

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

GlobeNewswireMay 14, 2024 07:30 ET

8-K: XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

SECMay 9, 2024 07:47 ET

10-Q: Q1 2024 Earnings Report

SECMay 9, 2024 07:37 ET · Announcements

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Stockhouse May 9, 2024 07:30 ET

XOMA Adds Economic Interests in Three First-in-Category Assets to Its Royalty and Milestone Portfolio Including XACIATO (Clindamycin Phosphate) Vaginal Gel 2%

GlobeNewswireApr 30, 2024 07:30 ET

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (Tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (PLGG)

GlobeNewswireApr 25, 2024 07:30 ET